Introduction
============

Early T-cell precursor-acute lymphoblastic leukemia (ETP-ALL) has been identified as a distinct biological subtype of T-cell lineage ALL (T-ALL), which accounts for 15% of T-ALL cases (and \~2% of ALL cases). It is associated with poor clinical outcomes even following the use of current treatment regimens. Recently, the complete remission rate/complete remission with incomplete platelet recovery rate in patients with ETP-ALL was indicated to be significantly lower than that of non-ETP-ALL patients (73 vs. 91%; P=0.03) in 2016 ([@b1-etm-0-0-5046]). Up to the last follow up, the median overall survival for patients with ETP-ALL was 20 months vs. not yet reached for the non-ETP-ALL/LBL patients (P=0.008) ([@b1-etm-0-0-5046]). This subtype is characterized by a lack of expression of the T-cell surface markers cluster of differentiation (CD) 1a and CD8, weak or absent expression of CD5, and aberrant expression of at least one of the following myeloid or hematopoietic stem cell markers: CD13, CD33, CD34, CD117, human leukocyte antigen (HLA)-DR, CD11b and CD65 ([@b2-etm-0-0-5046]).

T-ALL is a genetically heterogeneous disease caused by the accumulation of multiple genetic defects in developing T-cells that affect critical cellular processes, including cell differentiation, proliferation, survival and self-renewal capacity ([@b3-etm-0-0-5046]). The presence of the nucleoporin 214-ABL proto-oncogene 1 *(NUP214-ABL1)* fusion gene has been identified in 6% of all T-ALL cases ([@b4-etm-0-0-5046]). NUP214, also known as CAN, is a 214-kDa FG-repeat-containing nucleoporin located at band 9q34.1 and includes 36 exons. The encoded protein is located at the cytoplasmic side of the nuclear pore complex (NPC) ([@b5-etm-0-0-5046]). The NUP214-ABL1 fusion protein is a constitutively active protein tyrosine kinase. De Keersmaecker *et al* ([@b6-etm-0-0-5046]) recently identified that the sparse representation-based classifier (SRC) family kinase lymphocyte-specific protein tyrosine kinase (LCK) is a protein essential for the proliferation and survival of T-ALL cells dependent on NUP214-ABL1 activity. These findings underscore the potential of the dual ABL1/SRC kinase inhibitor dasatinib in the treatment of NUP214-ABL1-positive T-ALL. Furthermore, NUP214 serves a role in mRNA export and chromosome region maintenance 1 (CRM1)-mediated export of the 60S pre-ribosomal subunit, and may serve a role in the transport of other proteins ([@b7-etm-0-0-5046]). Given that CRM1 inhibitors, such as selinexor, suppress the export of proteins associated with NUP214 ([@b7-etm-0-0-5046]), there is potential for their use to treat patients with T-ALL that also harbor *NUP214-ABL1*.

The *NUP214-ABL1* gene is highly specific for T-ALL ([@b8-etm-0-0-5046]), however the prevalence of *NUP214-ABL1* gene expression in ETP-ALL has not been verified. Zhang *et al* ([@b9-etm-0-0-5046]) reported that *NUP214-ABL1* was not detected in all the 64 ETP-ALL cases studied. The present case report describes a rare case of a patient with ETP-ALL harboring the *NUP214-ABL1* fusion gene. The present study also evaluated the therapeutic efficiency of selinexor and dasatinib to treat *NUP214-ABL1*-positive ETP-ALL cells *in vitro*. ETP-ALL has higher rates of relapse and remission failure following conventional chemotherapy and shorter patient survival times ([@b1-etm-0-0-5046]), meaning that novel therapeutic agents to treat ETP-ALL are urgently required.

Case report
===========

A 29-year-old Han Chinese man was admitted to the Zhongshan Hospital, Xiamen University (Xiamen, China) in September 2015 with a low-grade fever and stomachache, which he had experienced for 5 days. The patient had no family history of genetic or hematological disease. Ethical approval for the current case report was granted by the Medical Ethics Committee of Zhongshan Hospital, Xianmen University (Xiamen, China) and informed written consent was obtained from the patient.

The patient presented with splenomegaly (spleen size, 13.2×4.3 cm) determined via abdominal ultrasonography. The patient\'s peripheral blood was analyzed with a hematology analyzer (Beckman Coulter, Inc., Brea, CA, USA): White blood cell count was 5.86×10^9^/l (neutrophils, 10%; lymphocytes, 66%; monocytes, 20%; reference range, white blood cell count 3.5×10^9^/l-9.5×10^9^/l; neutrophils, 50--70%; lymphocytes, 20--50%; monocytes, 3--10%), hemoglobin level (Hb) was 118 g/l (reference range, 130--175 g/l) and blood platelet count (Plat) was 45×10^9^/l (reference range, 125 ×10^9^/l-350 ×10^9^/l). The proportion of immature cells detected in the peripheral blood was low (4%). The following blood coagulation characteristics were measured: Prothrombin time, 15.6 sec (reference range, 11.0--15.0 sec); activated partial thromboplastin time, 15.2 sec (reference range, 28.0--42.5 sec); fibrinogen level, 2.82 g/l (reference range, 2.00--4.00 g/l) and D-dimer quantification, 3,150 ng/ml (reference range, 0.00--500.00 ng/ml. Lactate dehydrogenase levels were elevated (605.1 U/l; reference range, 109.0--245.0 U/l), however liver and renal functions were normal. The patient underwent bone marrow (BM) harvesting under general anesthesia. BM was aspirated from the posterior iliac crest in a sterile operating room, and BM smears stained with Wright-Giemsa stains (Electron Microscopy Sciences, Hatfield, PA, USA) were obtained and tested under an optical microscope. The white blood cell nucleus and cytoplasm were indicated by the characteristic blue or pink coloration. The 500-cell differential count from the BM aspirate on the first day of hospital admission revealed that 80% of all nucleated cells were blasts. The majority of blasts exhibited large sizes, high nuclear/cytoplasm ratios, irregularly shaped nuclei, dispersed chromatin, indistinct nucleoli and basophilic cytoplasm that occasionally formed pseudopods, but few exhibited moderate amounts of granular cytoplasm, fine nuclear chromatin and 2--3 prominent nucleoli ([Fig. 1A](#f1-etm-0-0-5046){ref-type="fig"}). Cytochemical staining ([@b10-etm-0-0-5046]) was negative for myeloperoxidase (MPO) and \~3% positive for periodic acid-Schiff staining.

Flow cytometry of the BM aspirate was performed using a four-color Beckman Coulter Cytomics FC 500 flow cytometer (Beckman Coulter, Inc.) as described previously ([@b11-etm-0-0-5046]). The results indicated that \~90% of the blasts were positive for CD45, the T-cell markers cCD3, CD2 and CD7, and the myeloid/stem cell markers CD34, CD38, CD13, CD33, HLA-DR and CD123. However, the blasts were weak for CD5, negative for CD1a, CD8, as well as CD19, CD10, CD79a, terminal deoxynucleotidyl transferase, CD4, CD3, CD64, CD14, CD20, CD56, CD16, CD15, CD11b and MPO ([Fig. 1B](#f1-etm-0-0-5046){ref-type="fig"}), suggesting a diagnosis of ETP-ALL. Bone marrow cells were directly processed for chromosomal preparation and cytogenetic analyses were performed using the standard method and/or the G-banding method ([@b12-etm-0-0-5046]). The result of conventional G-banding chromosomal analysis of the BM cells was 80--83\<4n\>,XXYY,+mar, inc\[2\]/46,XY\[18\] ([Fig. 2A](#f2-etm-0-0-5046){ref-type="fig"}).

The results of multiplex nested reverse transcription-polymerase chain reaction (RT-PCR), which was performed as described previously ([@b13-etm-0-0-5046]), were negative for the fusion genes listed in [Table I](#tI-etm-0-0-5046){ref-type="table"}. Multiplex RT-PCR was subsequently used to detect Philadelphia chromosome-like fusion genes that have a gene expression profile similar to that of Ph^+^ ALL, but lack *BCR ABL1* fusion. The results demonstrated that the NUP214-ABL1 fusion gene was positive in this case ([Table I](#tI-etm-0-0-5046){ref-type="table"}; [Fig. 2B](#f2-etm-0-0-5046){ref-type="fig"}), which was further confirmed by DNA sequencing ([Fig. 2C](#f2-etm-0-0-5046){ref-type="fig"}). Also, gene mutation analyses ([Table I](#tI-etm-0-0-5046){ref-type="table"}) were performed. A TET2 missense mutation (c.86C\>G; p.P29R), ASXL1 missense mutation (c.1954G\>A; p.G652S) and ASXL1 same-sense mutation (c.3759T\>C; p.S1253S) were detected in this case, which were single nucleotide polymorphism variants (SNP) of TET2 and ASXL1 mutations. These SNP variants did not suggest any significant prognostic impact on leukemia.

The patient received pretreatment with an intravenous drip of 10 mg/day dexamethasone (Cisen Pharmaceutical Co., Ltd., Shandong, China). Following treatment for 7 days, stomachache and fever were attenuated and the patient\'s lymphocyte count decreased to \<1.0×10^9^/l. The patient subsequently received induction chemotherapy with vincristine (Hangzhou Minsheng Pharmaceutical Group Co., Ltd., Hangzhou, China), idarubicin (Pfizer Inc., New York, NY, USA), cyclophosphamide (Baxter Oncology GmbH, Shanghai, China) and prednisone (Cisen Pharmaceutical Co., Ltd.) (VICP; 2 mg vincristine on days 1, 8, 15 and 22; 10 mg idarubicinon days 1--3 and days 15--17; 1.2 g cyclophosphamide on days 1 and 15; and 60 mg prednisone on days 1--28) and dasatinib (100 mg/day, on days 8--14). On day 15, routine blood examination results were as follows: Neutrophils, 4.76×10^9^/l; lymphocytes, 1.85×10^9^/l, Hb 65 g/l and Plat 74×10^9^/l (reference range, neutrophils, 1.8×10^9^/l-6.3×10^9^/l; lymphocytes, 1.10×10^9^/l-3.2×10^9^/l, Hb 130--175 g/l and Plat 125×10^9^/l-350×10^9^/l). BM aspiration revealed \<5% lymphoblasts, indicating that the patient had achieved a complete hematological remission with incomplete blood count recovery. On day 30, the patient had achieved complete hematological remission (CR), which was defined as \<5% marrow blasts in the bone marrow aspirate and normalization of blood counts. The patient then received consolidation chemotherapy \[1.2 g cyclophosphamide on day 1; 3 g cytarabine (Pfizer Inc.) every 12 h on days 1--2; and 80 mg 6-mercaptopurine (Hangzhou Minsheng Pharmaceutical Group Co., Ltd.) on days 1--7\] and adequate central nervous system prophylaxis with intrathecal therapy \[10 mg methotrexate (Pfizer Inc.), 50 mg cytarabine and 10 mg dexamethasone\] and high-dose systemic chemotherapy with 5 g/m^2^ methotrexate. The final date of follow-up was January 11 2016, at which point the patient was alive and healthy.

### In vitro analysis of selinexor and dasatinib treatment

Upon written informed consent, *in vitro* analysis was conducted on cells from the patient. A total of 2×10^6^ primary lymphoblast cells were obtained from BM samples using Ficoll density gradient centrifugation (FicollPaque PLUS solution; GE Healthcare Life Sciences, Little Chalfont, UK). The protocol was as follows: 4 ml of Ficoll Histopaque was placed in a 15 ml centrifuge tube, then the bone marrow sample was gently layered on top. The tubes were centrifuged for 30 min at 100 × g at 4°C in a swing-out bucket. The buffy coat that formed in the interphase between histopaque and medium was aspirated and washed (centrifuged at 100 × g for 10 min) twice with 10 ml of sterile PBS. Primary lymphoblast cells were maintained in RPMI 1640 medium (Thermo Fisher Scientific, Inc.) and 15% fetal calf serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), and incubated in an atmosphere containing 5% CO~2~ at 37°C. The effect of selinexor and dasatinib on apoptosis was evaluated in primary lymphoblast cells. The primary cells were treated with 10 µM selinexor ([@b14-etm-0-0-5046]) and/or 10 µM dasatinib ([@b15-etm-0-0-5046]) for 48 h at 37°C. Apoptosis was subsequently analyzed using the Annexin V/propidium iodide staining (BD PharMingen, San Diego, CA, USA) and flow cytometry was performed according to the manufacturer\'s protocol. Poly ADP-ribose polymerase (PARP) cleavage was detected using western blot analysis ([@b16-etm-0-0-5046]).

The results demonstrated that the apoptotic cell population significantly increased following selinexor or dasatinib treatment compared with the control (P\<0.05) and combined selinexor and dasatinib treatment led to a significant increase in cell apoptosis compared with either treatment alone (P\<0.05; [Fig. 3A](#f3-etm-0-0-5046){ref-type="fig"}). These results were further confirmed by the detection of increased PARP cleavage by western blot analysis following selinexor or dasatinib treatment, compared with the control ([Fig. 3B](#f3-etm-0-0-5046){ref-type="fig"}). Combined selinexor and dasatinib treatment induced more PARP cleavage than either treatment alone.

Discussion
==========

Approximately 8% of T-ALL cases harbor fusions involving the *ABL1* tyrosine kinase gene ([@b17-etm-0-0-5046]). BCR-ABL1, the prototypic ABL1 fusion kinase in chronic myeloid leukemia and subsets of B-cell ALL, is rarely detected in T-ALL ([@b18-etm-0-0-5046]). By contrast, 6% of T-ALL cases express the constitutively active NUP214-ABL1 fusion kinase ([@b5-etm-0-0-5046]). To the best of our knowledge, there have been no studies reporting *NUP214-ABL1* fusion gene expression in ETP-ALL to date. The current case report describes a rare case of ETP-ALL with *NUP214-ABL1* fusion gene expression. ETP-ALL is recognized as a form of T-ALL with high induction failure ([@b1-etm-0-0-5046]). However, CR was achieved in the current case following 30 days induction therapy with VICP and dasatinib. Further studies are required to confirm that dasatinib used in combination with traditional induction chemotherapy is more effective than chemotherapy alone.

The NUP214-ABL1 fusion protein is sensitive to tyrosine kinase inhibitors including imatinib, dasatinib and nilotinib ([@b17-etm-0-0-5046]); therefore, these drugs may have potential in treating this subgroup of patients with T-ALL. Although NUP214-ABL1 is sensitive to ABL1 kinase inhibitors, the development of resistance to these compounds is a major clinical problem, underlining the requirement for additional drug targets in the sparsely studied NUP214-ABL1 signaling network. De Keersmaecker *et al* ([@b6-etm-0-0-5046]) identified LCK, mitotic arrest deficient-like 1, structural maintenance of chromosomes protein 4 and nucleoporin 155 as proteins that NUP214-ABL1-positive T-ALL tumor cells depend on for their proliferation, indicating that these proteins are potential drug targets for NUP214-ABL1-positive T-ALL. Targeting LCK in NUP214-ABL1 may be possible to treat patients with T-ALL that are NUP214-ABL1-positive, as dasatinib and bosutinib are able to co-target ABL1 and LCK ([@b6-etm-0-0-5046]). The effect of dasatinib on the apoptosis of primary isolated lymphoblast cells from the patient in the present case study was evaluated. Following treatment for 48 h, apoptosis was induced, indicating that dasatinib induces a cytotoxic effect in NUP214-ABL1-positive cells.

Furthermore, De Keersmaecker *et al* ([@b8-etm-0-0-5046]) reported that incorporating NUP214-ABL1 into the NPC may be critical for the activation of NUP214-ABL1 kinase. NUP214 is one component of NPC proteins. Evolutionarily conserved NPC proteins mediate the transport of molecules between the nucleoplasm and cytoplasm, which are CRM1 dependent. Mutations in nucleoporins are often linked to specific developmental defects and disease, and the resulting phenotypes are usually interpreted as the consequences of perturbed nuclear transport activity ([@b8-etm-0-0-5046]). The present study indicated that CRM1 inhibition with selinexor was effective against a case of NUP214-ABL1-positive T-ALL *in vitro*. Therefore, selinexor may have a potential function as a salvage therapy at the time of relapse.

In conclusion, expression of the *NUP214-ABL1* fusion gene should be tested in cases of T-ALL, including ETP-ALL. Dasatinib in combination with traditional induction chemotherapy may reverse the high induction failure of ETP-ALL with *NUP214-ABL1* fusion gene, although further prospective studies are required to confirm this. Therefore, selinexor with or without dasatinib may serve as a potential salvage therapy following relapse.

![Histomorphological features of leukemic blasts from bone marrow aspirates and flow cytometry analysis. (A) Blasts were large and had high nuclear/cytoplasm ratios, irregular nuclei, dispersed chromatin pattern, indistinct nucleoli and basophilic cytoplasm with pseudopods (Wright-Giemsa stain, the white blood cell nucleus and cytoplasm are indicated by the characteristic blue or pink coloration; magnification, ×1,000). (B) Flow cytometric immunophenotyping.](etm-14-05-3979-g00){#f1-etm-0-0-5046}

![Karyotype of the abnormal clone and detection of the *NUP214-ABL1* fusion transcript. (A) Karyotype of the abnormal clone. The final karyotype was 80--83\<4n\>,XXYY,+ mar, inc \[2\]/46, XY\[18\]. (B) *NUP214-ABL1* fusion transcript detected by multiplex reverse transcription-polymerase chain reaction. (C) *NUP214-ABL1* fusion transcript detected by DNA sequencing. *NUP124* exon 32 and *ABL1* exon 2 are shaded blue. *NUP214-ABL1*, nucleoporin 214-tyrosine protein kinase ABL1 proto-oncogene 1.](etm-14-05-3979-g01){#f2-etm-0-0-5046}

![Effect of selinexor and dasatinib treatment in primary biopsy-derived *NUP214-ABL1*-positive lymphoblast cells. Freshly isolated lymphoblast cells were treated with 10 µM selinexor and/or 10 µM dasatinib for 48 h. (A) Apoptosis was measured using Annexin V/propidium iodide staining and flow cytometry. (B) Cell extracts were analyzed by western blot analysis to determine PARP cleavage. PARP, poly ADP-ribose polymerase; C, control; *NUP214-ABL1*, nucleoporin 214-tyrosine protein kinase ABL1 proto-oncogene 1.](etm-14-05-3979-g02){#f3-etm-0-0-5046}

###### 

Genetic analysis of the early T-cell precursor-acute lymphoblastic leukemia patient.

  Type of analysis       Gene           Method                       Result
  ---------------------- -------------- ---------------------------- -----------------------------------------------
  Gene mutation          FLT3-ITD       RT-PCR                       --
  Fusion gene            MLL/AF4        Multiplex nested             --
                                        RT-PCR                       
                         MLL/AF6                                     --
                         MLL/AF9                                     --
                         MLL/AF10                                    --
                         MLL/AF17                                    --
                         MLL/AF1P                                    --
                         MLL/AF1Q                                    --
                         MLL/AFX                                     --
                         MLL/ELL                                     --
                         MLL/ENL                                     --
                         dupMLL                                      --
                         CBFβ/MYH11                                  --
                         AML1/ETO                                    --
                         AML1/MDS1                                   --
                         SET/CAN                                     --
                         DEK/CAN                                     --
                         PML/RARα                                    --
                         PLZF/RARα                                   --
                         NPM/RARα                                    --
                         NPM/ALK                                     --
                         TEL/AML1                                    --
                         E2A/PBX1                                    --
                         BCR/ABL1                                    --
                         NPM/MLF1                                    --
                         TEL/ABL1                                    --
                         E2A/HLF                                     --
                         TLS/ERG                                     --
                         SIL/TAL1                                    --
                         TEL/PDGFR                                   --
                         EVI1                                        --
                         HOX11                                       --
  Ph-like fusion genes   RCSD1/ABL1     Multiplex RT-PCR             --
                         ZMIZ1/ABL1                                  --
                         NUP214/ABL1                                 \+
                         PAG/ABL2                                    --
                         TNIP1/PDGFRβ                                --
                         RANBP2/ABL1                                 --
                         SNX2/ABL1                                   --
                         RCSD1/ABL2                                  --
                         SSBP2/PDGFRβ                                --
                         ETV6/ABL1                                   --
                         ZC3HAV1/ABL2                                --
                         ZEB2/PDGFRβ                                 --
                         TEL/ABL1                                    --
                         SSBP2/CSF1R                                 --
                         EBF1/PDGFRβ                                 --
  Gene mutation          FLT3-ITD       RT-PCR                       --
                         IDH1^R132^     Next-generation sequencing   --
                         NPM1(exon12)                                --
                         IDH2R140                                    --
                         CEBPA                                       --
                         IDH2R172                                    --
                         DNMT3A                                      --
                         C-kitD816                                   --
                         PHF6                                        --
                         TET2                                        (c.86C\>G; p.P29R)
                         ASXL1                                       (c.1954G\>A; p.G652S), (c.3759T\>C; p.S1253S)

RT-PCR, reverse transcription-polymerase chain reaction; +, positive; -, negative; Ph-like, Philadelphia chromosome-like.
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